南方医科大学学报
南方醫科大學學報
남방의과대학학보
JOURNAL OF SOUTHERN MEDICAL UNIVERSITY
2013年
12期
1713-1717
,共5页
毛英%方廖琼%刘隆兴%胡海霞%李发琪%朱辉
毛英%方廖瓊%劉隆興%鬍海霞%李髮琪%硃輝
모영%방료경%류륭흥%호해하%리발기%주휘
高强度聚焦超声%胰腺癌%吉西他滨
高彊度聚焦超聲%胰腺癌%吉西他濱
고강도취초초성%이선암%길서타빈
high-intensity focused ultrasound%pancreatic cancer%gemcitabine
目的:通过高强度聚焦超声(HIFU)及化疗药物(吉西他滨)作用于人胰腺癌裸鼠皮下移植瘤,评估HIFU及化疗对异位移植瘤的疗效。方法构建人胰腺癌裸鼠皮下移植瘤模型,设定为HIFU组,化疗组,HIFU联合化疗组及对照组,治疗后每周测量肿瘤长径、短径、共观察5周,绘制肿瘤曲线,计算抑瘤率,并通过免疫组化检测瘤组织中血管内皮生长因子的表达水平。结果各治疗组肿瘤体积差异显著(P<0.01),均明显小于对照组,差异显著(P<0.01),差异最显著为对照组与联合治疗组之间(P<0.001)。HIFU联合化疗组抑瘤率最明显,与单化疗及单HIFU组差异显著。血管内皮细胞生长因子表达在联合组水平最低,对照组水平最高。结论HIFU治疗胰腺癌异位移植瘤疗效确切,能明显延缓肿瘤进展,HIFU联合化疗为最佳治疗模式。
目的:通過高彊度聚焦超聲(HIFU)及化療藥物(吉西他濱)作用于人胰腺癌裸鼠皮下移植瘤,評估HIFU及化療對異位移植瘤的療效。方法構建人胰腺癌裸鼠皮下移植瘤模型,設定為HIFU組,化療組,HIFU聯閤化療組及對照組,治療後每週測量腫瘤長徑、短徑、共觀察5週,繪製腫瘤麯線,計算抑瘤率,併通過免疫組化檢測瘤組織中血管內皮生長因子的錶達水平。結果各治療組腫瘤體積差異顯著(P<0.01),均明顯小于對照組,差異顯著(P<0.01),差異最顯著為對照組與聯閤治療組之間(P<0.001)。HIFU聯閤化療組抑瘤率最明顯,與單化療及單HIFU組差異顯著。血管內皮細胞生長因子錶達在聯閤組水平最低,對照組水平最高。結論HIFU治療胰腺癌異位移植瘤療效確切,能明顯延緩腫瘤進展,HIFU聯閤化療為最佳治療模式。
목적:통과고강도취초초성(HIFU)급화료약물(길서타빈)작용우인이선암라서피하이식류,평고HIFU급화료대이위이식류적료효。방법구건인이선암라서피하이식류모형,설정위HIFU조,화료조,HIFU연합화료조급대조조,치료후매주측량종류장경、단경、공관찰5주,회제종류곡선,계산억류솔,병통과면역조화검측류조직중혈관내피생장인자적표체수평。결과각치료조종류체적차이현저(P<0.01),균명현소우대조조,차이현저(P<0.01),차이최현저위대조조여연합치료조지간(P<0.001)。HIFU연합화료조억류솔최명현,여단화료급단HIFU조차이현저。혈관내피세포생장인자표체재연합조수평최저,대조조수평최고。결론HIFU치료이선암이위이식류료효학절,능명현연완종류진전,HIFU연합화료위최가치료모식。
Objective To investigate the effect of high-intensity focused ultrasound (HIFU) and gemcitabine on xenograft growth in nude mice bearing human pancreatic cancer. Methods Nude mouse models bearing subcutaneous human pancreatic cancer cell line PANC-1 xenograft were randomized into 4 groups, including a control group and 3 treatment groups subjected to treatments with HIFU, gemcitabine, or both. After the treatments, the tumor was measured on a weekly basis for 5 weeks, and the tumor growth curve was drawn. The tumor inhibition rate was calculated and the expression of vascular endothelial growth factor (VEGF) in the tumor tissue was examined by immunohistochemistry. Results The tumor volume showed significant differences between the 3 treatment groups (P<0.01), but all significantly smaller than that in the control group; HIFU combined with gemcitabine resulted in the most obvious reduction in the tumor volume. VEGF expression in the tumor tissue was the lowest in the combined treatment group and the highest in the control group. Conclusion HIFU therapy produces definite therapeutic effect on human pancreatic cancer in the nude mouse model, and its combination with chemotherapy is the optimal treatment modality.